Background and Purpose
Recurrent glioblastoma patients often exhibit regions of diffusion restriction following the initiation of bevacizumab therapy. Studies suggest these regions represent either diffusion restricted necrosis or hypercellular tumor. This study explores autopsy brain specimens and a population analysis of overall survival to determine the identity and implications of such lesions.
Methods
Autopsies were performed on six recurrent glioblastoma patients on bevacizumab with progressively growing regions of diffusion restriction. ADC values were extracted from regions of both hypercellular tumor and necrosis. A receiver operating characteristic analysis was performed to define optimal ADC thresholds for differentiating tissue types. A retrospective population study was also performed comparing the OS of sixty-four recurrent glioblastoma patients treated with bevacizumab. Patients were separated into three groups: no diffusion restriction, diffusion restriction that appeared and progressed within 5 months of bevacizumab onset, and delayed or stable diffusion restriction. An additional analysis was done assessing tumor O6-methylguanine-DNA-methyltransferase methylation.
Results
The optimal ADC threshold for differentiation between hypercellularity and necrosis was 0.736×10−3mm2/s. Progressively expanding diffusion restriction was pathologically confirmed to be coagulative necrosis surrounded by viable tumor. Progressive lesions were associated with the worst overall survival while stable lesions showed greatest (p<0.05). Of the 40% of patients with O6-methylguanine-DNA-methyltransferase methylated tumors, none developed diffusion-restricted lesions.
Conclusion
Progressive diffusion-restricted lesions were pathologically confirmed to be coagulative necrosis surrounded by viable tumor and associated with decreased overall survival. Stable lesions were however associated with increased overall survival. All lesions were associated with O6-methylguanine-DNA-methyltransferase unmethylated tumors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.